BioMonde’s Biosurgical Debridement Product BioBag is Now Available on the VA Federal Supply Schedule (FSS)
BioMonde awarded Federal Supply Schedule contract
GAINESVILLE, Fla.–(BUSINESS WIRE)–BioMonde US, LLC announced that the BioBag product range has been
awarded a contract on the Veterans Affairs (VA) Federal Supply Schedule.
This successful award comes after BioMonde has been conducting business
in the US since the launch of the BioBag in 2014. This contract award
enables BioMonde to provide the BioBag product range to the largest
integrated healthcare system in the US; the FSS services the VA and
other federal government agencies such as the Indian Health Service and
the Department of Defense. This means that BioBag is now available to
nearly 9 million VA patients of which up to 25% present with diabetes.
BioBag – innovation of an old concept
BioBag is both a clinically and cost effective way for clinicians to
treat non-healing wounds such as pressure ulcers, diabetic ulcers,
surgical wounds, traumatic wounds and venous stasis ulcers. BioBag
contains all the known benefits of Larval Therapy in a quick and
easy-to-use contained dressing. Ease of application, rapid debridement
times, and economical product costs make BioBag an efficient debridement
solution for all non-healing wounds.
Each of the five available sizes in the BioBag product range (BB50,
BB100, BB200, BB300 and BB400) have been awarded the contract under
Schedule 65 II A – Medical Equipment and Supplies.
BioMonde’s commitment
BioMonde is dedicated to improving outcomes of non-healing wounds within
the Veterans Affairs Health System. BioMonde is currently sponsoring a
140 patient clinical trial through the Center of Innovation on
Disability and Rehabilitation Research (CINDRR) at the Malcom Randall VA
Medical Center in Gainesville, Florida. This outpatient study compares
the removal of bacterial biofilm in sharp debridement (control) versus
BioBag in non-healing diabetic foot ulcers and leg ulcers.
BioMonde US LLC
CEO Gareth Kempson said that “BioMonde have long known how beneficial
BioBag can be for patients within the Veterans Affairs and Indian Health
System. We are delighted that this treatment is now available through
FSS. We are extremely confident that BioBag can make a significant and
positive difference to the treatment of Veterans and patients of the
Indian Health Service and assist in not only providing cost effective
care and improved clinical outcomes but also by delivering an
improvement to the quality of life for them and their family.”
BioMonde have a specialist manufacturing site at the Innovation Hub at
the University of Florida in Gainesville. BioMonde secured financial
backing from Finance Wales and Oxford Capital in 2014 after the European
company received FDA 510(k) approval for the patented debridement
product BioBag. BioBag is available nationally with local product
support available in most major cities within the US.
You can find the BioBag
FSS catalog listing here.
For more information about BioBag please visit http://biomonde.com/us/
or call 1.844.434.8529.
Caution: Federal law restricts this device to sale by or on the order of
a licensed healthcare practitioner.
Note: Information on the warnings, side effects, indications and
contraindications can be found by visiting http://biomonde.com/us/health-care-professionals.
Contacts
BioMonde, LLC
Katy Nicell, 352-294-7162
knicell@BioMonde.com
